EDNRA and focal segmental glomerulosclerosis: ETAR antagonists have been proven to delay the progression of chronic kidney disease (CKD) and play a protective role in IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), and diabetic nephropathy (DN) [3,4,5,6,7].